Gleevec is owned by Novartis.
Gleevec contains Imatinib Mesylate.
Gleevec has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Gleevec are:
Gleevec was authorised for market use on 10 May, 2001.
Gleevec is available in capsule;oral dosage forms.
The generics of Gleevec are possible to be released after 19 June, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|NOVARTIS||Treatment of gastrointestinal stromal tumors|| |
(9 months ago)
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic